Back to Search Start Over

GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi.

Authors :
Vader, M J C
Madigan, M C
Versluis, M
Suleiman, H M
Gezgin, G
Gruis, N A
Out-Luiting, J J
Bergman, W
Verdijk, R M
Jager, M J
van der Velden, P A
Source :
British Journal of Cancer; 9/5/2017, Vol. 117 Issue 6, p884-887, 4p, 2 Color Photographs, 1 Chart
Publication Year :
2017

Abstract

<bold>Background: </bold>Mutations in GNAQ/11 genes are considered an early event in the development of uveal melanoma that may derive from a pre-existing nevus. The Hippo pathway, by way of YAP activation, rather than MAP kinase, has a role in the oncogenic capacity of GNAQ/11 mutations.<bold>Methods: </bold>We investigated 16 nevi from 13 human eyes for driver GNAQ/11 mutations using droplet digital PCR and determined whether nevi are clonal by quantifying mutant nevus cell fractions. Immunohistochemistry was performed on 15 nevi to analyse YAP activation.<bold>Results: </bold>For 15 out of 16 nevi, a GNAQ/11 mutation was detected in the nevus cells albeit at a low frequency with a median of 13%. Nuclear YAP, a transcriptional co-activator in the Hippo tumour-suppressor pathway, was detected in 14/15 nevi.<bold>Conclusions: </bold>Our analysis suggests that a mutation in GNAQ/11 occurs in a subset of choroidal nevus cells. We hypothesise that GNAQ/11 mutant-driven extracellular mitogenic signalling involving YAP activation leads to accumulation of wild-type nevus cells. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00070920
Volume :
117
Issue :
6
Database :
Complementary Index
Journal :
British Journal of Cancer
Publication Type :
Academic Journal
Accession number :
124991945
Full Text :
https://doi.org/10.1038/bjc.2017.259